Trial · NCT07487948
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in IFNγ in CA scalp in delgocitinib-treated patients | Baseline to Week 36 | Changes in Th1 markers in CA scalp from baseline to week 36 in delgocitinib-treated patients |
| Primary | Changes in CCL5 in CA scalp in delgocitinib-treated patients | Baseline to Week 36 | Changes in Th1 markers in CA scalp from baseline to week 36 in delgocitinib-treated patients |
| Primary | Changes CXCL9 markers in CA scalp in delgocitinib-treated patients | Baseline to Week 36 | Changes in Th1 markers in CA scalp from baseline to week 36 in delgocitinib-treated patients |
| Primary | Changes in CXCL10 in CA scalp in delgocitinib-treated patients | Baseline to Week 36 | Changes in Th1 markers in CA scalp from baseline to week 36 in delgocitinib-treated patients |
| Secondary | Changes in IFNγ in CA scalp in delgocitinib-treated patients | Week 36 to Week 48 | Changes in Th1 markers in CA scalp from baseline to week 48 and from week 36 to week 48 |
| Secondary | Changes in CCL5 in CA scalp in delgocitinib-treated patients | Week 36 to Week 48 | Changes in Th1 markers in CA scalp from baseline to week 48 and from week 36 to week 48 |
| Secondary | Changes in CXCL9 in CA scalp in delgocitinib-treated patients | Week 36 to Week 48 | Changes in Th1 markers in CA scalp from baseline to week 48 and from week 36 to week 48 |
| Secondary | Changes in Th1 markersCXCL10in CA scalp in delgocitinib-treated patients | Week 36 to Week 48 | Changes in Th1 markers in CA scalp from baseline to week 48 and from week 36 to week 48 |
| Secondary | Changes in TGFB1/2 | Baseline to Week 36; Baseline to Week 48 | Changes in biomarkers of fibrosis at weeks 36 and at weeks 48 |
| Secondary | Changes in vimentin | Baseline to Week 36; Baseline to Week 48 | Changes in biomarkers of fibrosis at weeks 36 and at weeks 48 |
| Secondary | Changes in fibronectin | Baseline to Week 36; Baseline to Week 48 | Changes in biomarkers of fibrosis at weeks 36 and at weeks 48 |
| Secondary | Changes in CTGF | Baseline to Week 36; Baseline to Week 48 | Changes in biomarkers of fibrosis at weeks 36 and at weeks 48 |
| Secondary | Change in Central Hair Loss Grade (CHLG) | Baseline to Week 24; Baseline to Week 36; Baseline to Week 48 | The Central Hair Loss Grade is a clinical measure of severity that uses a 6 points scale (0 no central scalp hair loss, 1 - minimal central scalp hair loss, 2 - clinically evident central scalp hair loss, 3-5 advanced central scalp hair loss) |
| Secondary | Change in Lichen Planopilaris Activity Index (LPPAI) | Baseline to Week 24; Baseline to Week 36; Baseline to Week 48 | The Lichen Planopilaris Activity Index is a standardized validated quantitative measure of disease activity. LPPAI score (0-10) is calculated as follows: (pruritus + pain + burning)/3 + (scalp erythema + perifollicular erythema + perifollicular scale)/3 + 2.5 (pull test) + 1.5 (spreading/2). Symptoms and signs are graded on a 4-point scale with 0 = absent, 1 = mild, 2 = moderate, and 3 =severe. Clinical progression and a positive hair pull test are graded 1=yes; 0=no. |
| Secondary | Molecular cutaneous phenotype of CCCA and LPP by molecular studies in scalp tissues acquired via biopsies | Baseline to Week 48; Week 24 to Week 48 | An Analysis of Covariance will be used to analyze the changes induced by Delgocitinib in CCL5 (a surrogate for IFNγ activity) and biomarkers of fibrosis expression in CA scalp from baseline to week 48 and from week 24 to week 48. |
| Secondary | Change in Dermatology Quality of Life Index (DLQI) | Baseline to Week 24, Baseline to Week 36, Baseline to Week 48 | Full score on scale from 0 to 30, with higher indicating higher impact on quality of life. |
| Secondary | Change in hair count per cm2 | Baseline to Week 24; Baseline to Week 36; Baseline to Week 48 | Change in number of hairs present in a 1cm2 area |
| Secondary | Change in sum of hair width per cm2 | Baseline to Week 24; Baseline to Week 36; Baseline to Week 48 | Change in total hair diameter in a 1cm2 area |
| Secondary | Change in terminal:vellus ratio | Baseline to Week 24; Baseline to Week 36; Baseline to Week 48 | Change in the ratio of thick pigmented long hair to fine-barely visible hairs |
| Secondary | Change in average hairs per follicular unit | Baseline to Week 24; Baseline to Week 36; Baseline to Week 48 | Change in average number of hairs growing out of each pore |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07487948/registered